The promising preliminary survival and remission outcomes that inotuzumab ozogamicin produced in relapsed or refractory acute lymphoblastic leukemia patients in the antibody-drug conjugate’s Phase 3 trial have been sustained in a long-term follow-up study.
Blinatumomab Trial: 66 Percent of Patients Achieve Remission from Acute Lymphoblastic Leukemia
Remission rates of elderly ALL patients on a novel, lower-toxicity immunotherapy regimen appear to at least equal those observed with conventional chemotherapy.
Inotuzumab Ozogamicin Improves Outcomes for Relapsed/Refractory Acute Lymphoblastic Leukemia
Patients with relapsed/refractory ALL who were treated in a clinical trial with the antibody-drug conjugate inotuzumab ozogamicin experienced much higher remission rates compared with the standard of care, a new study reports.
Vadastuximab for AML: Investigator Predicts Changes to Standard Therapy in Near Future
AML studies report effectiveness of vadastuximab, an anti-CD33 drug conjugate, in various regimens including combined with azacitidine and as part of maintenance regimens. Investigators predict changes to standard treatment of AML in the near future.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Novel Agent Holds Promise for Refractory/Relapsed ALL
The prognosis for ALL is poor and therapy has not changed for a decade. The drug inotuzumab ozogamicin now holds promise to change that outlook and improve outcomes.
Evaluating Novel Therapies in Acute Leukemia
Several promising antibody-based treatment strategies are in development for acute lymphoblastic leukemia and acute myeloid leukemia. These could change the decade-old treatment paradigm.
Treating Young Adults with Acute Lymphoblastic Leukemia
Early study results show significant improvement for young adult acute lymphoblastic leukemia patients on pediatric treatment regimen as compared to conventional adult regimens.
Novel Antibody-Drug Conjugate Targets CD33-Positive AML
Seattle Genetics has developed a novel antibody-drug conjugate that shows promise in treating patients with CD33-positive acute myeloid leukemia. SGN-CD33A targets cells expressing CD33.